Recipham to Expand Lyophilization Capacity in Germany

Published on: 

Recipharm has invested EUR 32 million ($43 million) in its Wasserburg, Germany site to expand lyophilization capacity.

Recipharm will invest EUR 32 million ($43 million) in its Wasserburg, Germany site located near Munich to create a new building that will house a fourth production area adding to the three already in operation. This development will increase the company’s lyophilization capacity and automatic loading and unloading technology. The building will also have the flexibility to accommodate further production lines.  The number of employees will be increased from the current 282 to 320, and the new area is expected to be operational in 2016.
 
Source: Recipharm

Related Content:

Industry NewsOutsourcingManufacturingManufacturing ServicesSupplier NewsManufacturing, Parenterals and InjectablesManufacturing, LyophilizationContract Manufacturing, Finished Drug Product
FDA Reports on Status of Postmarketing Requirements and Postmarketing Commitments
Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients
Increasing mRNA Product Stability with Lyophilization